Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

NCT06408168 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped \<75% Participation

Conditions

Hormone Receptor-positive Human Epidermal Growth Factor 2-negative
Metastatic Invasive LObular Carcinoma

Interventions

DRUG: Fulvestrant
DRUG: Repotrectinib

Sponsor

M.D. Anderson Cancer Center